Physician profile
Katherine E Smith
NPI 1144719535
$5,488.65
in general payments reported to CMS, 2019-2025
25 companies · $1,778 in 2025
The $1,778 reported for 2025 was more than what 92% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $647 · 2022: $1,123 · 2023: $835 · 2024: $1,107 · 2025: $1,778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,959 · Travel and Lodging: $716 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,958.93 |
| Travel and Lodging | $715.50 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,201.58 | 2021-2025 | Intellis Adaptivestim, Accurian, Inceptiv |
| Abbvie INC. | $827.06 | 2021-2025 | |
| Abbott Laboratories | $620.29 | 2021-2025 | Eterna, Proclaim |
| Collegium Pharmaceutical, INC. | $301.03 | 2021-2025 | Xtampza, Belbuca |
| Nevro Corp. | $252.39 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $205.02 | 2021-2025 | Ajovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.91 | 2022-2024 | Relistor |
| Pfizer INC. | $117.98 | 2021-2024 | |
| Merz Pharmaceuticals, LLC | $112.43 | 2021-2023 | Xeomin |
| Biohaven Pharmaceutical Holding Company Ltd. | $106.92 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $95.09 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $64.07 | 2024-2025 | |
| Ibsa Pharma INC. | $61.01 | 2021-2024 | Tirosint, Licart, Tirosint |
| Averitas Pharma INC. | $58.40 | 2023 | Qutenza |
| Amgen INC. | $52.39 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $51.02 | 2021-2023 | |
| Grt US Holding, INC. | $46.99 | 2022 | |
| Alnylam Pharmaceuticals INC. | $39.74 | 2022 | |
| Lilly USA, LLC | $28.65 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $22.99 | 2024 | Iovera |
| Globus Medical, INC. | $21.96 | 2025 | Senza |
| Lundbeck LLC | $17.62 | 2023 | Vyepti |
| Depuy Synthes Sales INC. | $17.60 | 2024 | Monovisc |
| Pacira Therapeutics, INC. | $15.01 | 2021 | |
| Eisai INC. | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.